Education
About Us
Working with TipRanks
Follow Us
Alumis Inc. (ALMS)
:ALMS
ALMS Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ALMS Stock 12 Month Forecast
Average Price Target
$19.40
▲(369.73% Upside)
| Highest Price Target$25.00 | Average Price Target$19.40 | Lowest Price Target$14.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Wells Fargo
$17
Buy
311.62%
Upside
Initiated
07/25/25
H.C. Wainwright
$14
Buy
238.98%
Upside
Reiterated
07/25/25
Alumis Inc.: Buy Rating Affirmed Amid Promising ESK-001 Developments and Strong Financial ProjectionsValuation and Risks. Using a discounted cash flow (DCF)-based valuation approach, we derive a firm value of $1.6B and a 12-month price objective of $14 per share, which includes the estimated end-2025 cash position of ~$408M and ~118M shares outstanding.
Leerink Partners
―
Buy
―
Reiterated
07/24/25
Alumis Inc.: Promising Pipeline and Strategic Advancements Justify Buy RatingWe see development of ESK-001 as de-risked based on positive data for BMY's (OP, the PAISLEY and, more recently, the PAISLEY CLE studies, in which TYK2 inhibition has been shown to be an effective therapeutic modality. Recall, TYK2 inhibition was also viewed favorably by rheumatology KOLs we hosted during our recent I&I Therapeutics Forum (see our note HERE). Moreover, beyond development of ESK-001 in SLE, we note that near-term investor focus remains on topline data from ALMS' Phase 3 ONWARD program of ESK-001 in plaque psoriasis (PsO), where topline data are expected in early 1Q26 (see our note HERE). ALMS is also planning a Phase 2 trial of A-005 (CNS-penetrant TYK2i) in multiple sclerosis (MS), expected to start in 2H25 with topline data possible in 2026.
Guggenheim
$18
Buy
335.84%
Upside
Initiated
06/10/25
Morgan Stanley
$23
Buy
456.90%
Upside
Initiated
06/01/25
Oppenheimer
$26→$25
Buy
505.33%
Upside
Reiterated
05/15/25
Cantor Fitzgerald
―
Buy
―
Reiterated
03/20/25
Robert W. Baird
$25→$17
Buy
311.62%
Upside
Reiterated
02/07/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wells Fargo
$17
Buy
311.62%
Upside
Initiated
07/25/25
H.C. Wainwright
$14
Buy
238.98%
Upside
Reiterated
07/25/25
Alumis Inc.: Buy Rating Affirmed Amid Promising ESK-001 Developments and Strong Financial ProjectionsValuation and Risks. Using a discounted cash flow (DCF)-based valuation approach, we derive a firm value of $1.6B and a 12-month price objective of $14 per share, which includes the estimated end-2025 cash position of ~$408M and ~118M shares outstanding.
Leerink Partners
―
Buy
―
Reiterated
07/24/25
Alumis Inc.: Promising Pipeline and Strategic Advancements Justify Buy RatingWe see development of ESK-001 as de-risked based on positive data for BMY's (OP, the PAISLEY and, more recently, the PAISLEY CLE studies, in which TYK2 inhibition has been shown to be an effective therapeutic modality. Recall, TYK2 inhibition was also viewed favorably by rheumatology KOLs we hosted during our recent I&I Therapeutics Forum (see our note HERE). Moreover, beyond development of ESK-001 in SLE, we note that near-term investor focus remains on topline data from ALMS' Phase 3 ONWARD program of ESK-001 in plaque psoriasis (PsO), where topline data are expected in early 1Q26 (see our note HERE). ALMS is also planning a Phase 2 trial of A-005 (CNS-penetrant TYK2i) in multiple sclerosis (MS), expected to start in 2H25 with topline data possible in 2026.
Guggenheim
$18
Buy
335.84%
Upside
Initiated
06/10/25
Morgan Stanley
$23
Buy
456.90%
Upside
Initiated
06/01/25
Oppenheimer
$26→$25
Buy
505.33%
Upside
Reiterated
05/15/25
Cantor Fitzgerald
―
Buy
―
Reiterated
03/20/25
Robert W. Baird
$25→$17
Buy
311.62%
Upside
Reiterated
02/07/25
Best Analysts Covering Alumis Inc.
1 Month
xxx
Success Rate
2/4 ratings generated profit
Average Return
+4.15%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +4.15% per trade.
3 Months
xxx
Success Rate
1/4 ratings generated profit
Average Return
-20.38%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -20.38% per trade.
1 Year
Success Rate
2/8 ratings generated profit
Average Return
-35.83%
reiterated a buy rating 16 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -35.83% per trade.
2 Years
xxx
Success Rate
2/8 ratings generated profit
Average Return
-35.69%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -35.69% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ALMS Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
14
14
13
5
5
Buy
3
3
3
1
2
Hold
2
2
2
1
0
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
20
20
19
7
7
Each month's total comprises the sum of three months' worth of ratings.
ALMS Financial Forecast
ALMS Stock Forecast FAQ
What is ALMS’s average 12-month price target, according to analysts?
Based on analyst ratings, Alumis Inc.’s 12-month average price target is 19.40.
What is ALMS’s upside potential, based on the analysts’ average price target?
Alumis Inc. has 369.73% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ALMS a Buy, Sell or Hold?
Alumis Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Alumis Inc.’s price target?
The average price target for Alumis Inc. is 19.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $14.00. The average price target represents 369.73% Increase from the current price of $4.13.
The highest analyst price target is $25.00 ,the lowest forecast is $14.00. The average price target represents 369.73% Increase from the current price of $4.13.
What do analysts say about Alumis Inc.?
Alumis Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of ALMS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.